RxDoctor Payments Data

Deidre Peacock, NP

Nurse Practitioner · Tifton, GANPI 1982094298

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 71 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • Lilly USA, LLC$188
  • AbbVie$171
  • GSK$165
  • Pfizer$109
  • Astellas Pharma US Inc$102
  • plus $305 from 10 others

What the payments were for

  • Food & beverage$1,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,260 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$19,996
Medicare patients
109
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide309$385,436
OzempicSemaglutide108$130,018
JardianceEmpagliflozin111$111,404
EliquisApixaban87$66,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$63,552
Tresiba Flextouch U-200Insulin Degludec78$58,201
LinzessLinaclotide38$39,133
Emgality PenGalcanezumab-Gnlm38$38,262
VraylarCariprazine Hcl17$27,723
FarxigaDapagliflozin Propanediol19$23,775
KerendiaFinerenone17$23,161
XareltoRivaroxaban27$21,445
Tresiba Flextouch U-100Insulin Degludec24$17,169
TradjentaLinagliptin21$16,034
VascepaIcosapent Ethyl29$13,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$188$385,436309 claims
Novo NordiskOzempic, Rybelsus$220$142,623121 claims
Boehringer IngelheimJardiance, Tradjenta$18$127,437132 claims
AbbVieLinzess, Vraylar, Synthroid$171$70,104104 claims
GSKTrelegy Ellipta, Breo Ellipta$165$69,68793 claims
PfizerEliquis$109$66,27187 claims
AstraZenecaFarxiga$14$23,77519 claims
BayerKerendia$20$23,16117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →